Revertants of poliovirus escape mutants: new insights into antigenic structures. 1993

R Ketterlinus, and K Wiegers, and R Dernick
Heinrich-Pette-Institut für Experimentelle Virologie und Immunologie, Universität Hamburg, Germany.

Poliovirus variants that escape neutralization by monoclonal antibodies (mAbs) have previously been selected and characterized in order to determine antigenic sites on the surface of the virion. Phenotypic revertants of poliovirus type 1 escape mutants were selected within all three antigenic sites (sites 1, 2, and 3) on the basis of their reactivity with the selecting mAb. The phenotypic and genotypic properties of these revertants were determined by binding and neutralization assays. Sequencing of the viral RNA revealed different types of reversions. Besides reversion to wild-type genotype, we found phenotypic revertants which had amino acid substitutions differing from wild type, thus revealing amino acids that are also tolerated by the antibody. In another type of revertant, alterations in other parts of the epitope were found, providing a refined resolution of a particular antibody recognition site. Most of the revertants regained the property to be neutralized by the mAb. However, in one case they remained resistant to neutralization despite the fact that binding to the selecting antibody was reestablished. These results indicate that virus neutralization might be achieved by different mechanisms depending on the particular mAb.

UI MeSH Term Description Entries
D007525 Isoelectric Focusing Electrophoresis in which a pH gradient is established in a gel medium and proteins migrate until they reach the site (or focus) at which the pH is equal to their isoelectric point. Electrofocusing,Focusing, Isoelectric
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000956 Antigens, Viral Substances elaborated by viruses that have antigenic activity. Viral Antigen,Viral Antigens,Antigen, Viral
D001483 Base Sequence The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence. DNA Sequence,Nucleotide Sequence,RNA Sequence,DNA Sequences,Base Sequences,Nucleotide Sequences,RNA Sequences,Sequence, Base,Sequence, DNA,Sequence, Nucleotide,Sequence, RNA,Sequences, Base,Sequences, DNA,Sequences, Nucleotide,Sequences, RNA
D012367 RNA, Viral Ribonucleic acid that makes up the genetic material of viruses. Viral RNA
D016297 Mutagenesis, Site-Directed Genetically engineered MUTAGENESIS at a specific site in the DNA molecule that introduces a base substitution, or an insertion or deletion. Mutagenesis, Oligonucleotide-Directed,Mutagenesis, Site-Specific,Oligonucleotide-Directed Mutagenesis,Site-Directed Mutagenesis,Site-Specific Mutagenesis,Mutageneses, Oligonucleotide-Directed,Mutageneses, Site-Directed,Mutageneses, Site-Specific,Mutagenesis, Oligonucleotide Directed,Mutagenesis, Site Directed,Mutagenesis, Site Specific,Oligonucleotide Directed Mutagenesis,Oligonucleotide-Directed Mutageneses,Site Directed Mutagenesis,Site Specific Mutagenesis,Site-Directed Mutageneses,Site-Specific Mutageneses

Related Publications

R Ketterlinus, and K Wiegers, and R Dernick
January 2003, Virology,
R Ketterlinus, and K Wiegers, and R Dernick
October 2001, Trends in microbiology,
R Ketterlinus, and K Wiegers, and R Dernick
January 2006, Journal of experimental botany,
R Ketterlinus, and K Wiegers, and R Dernick
August 2015, Antimicrobial agents and chemotherapy,
R Ketterlinus, and K Wiegers, and R Dernick
May 1967, Journal of molecular biology,
R Ketterlinus, and K Wiegers, and R Dernick
April 1983, The Journal of general virology,
R Ketterlinus, and K Wiegers, and R Dernick
July 2017, Molecular oncology,
R Ketterlinus, and K Wiegers, and R Dernick
June 1984, Biochemical Society transactions,
R Ketterlinus, and K Wiegers, and R Dernick
March 1996, Circulation research,
Copied contents to your clipboard!